Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.240
-0.200 (-8.20%)
Mar 24, 2026, 10:36 AM EDT - Market open

Allogene Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
5463144525419092,128
Market Cap Growth
19.47%-30.47%-16.50%-40.41%-57.30%-39.98%
Enterprise Value
427.86139.13242.78180.99486.321,741
Last Close Price
2.241.372.133.216.2914.92
PE Ratio
--1.57-1.61-1.54-2.64-11.13
PS Ratio
--20545.845698.335823.8318.65
PB Ratio
1.911.071.071.061.362.30
P/TBV Ratio
1.691.030.980.981.352.19
P/FCF Ratio
--2.10-2.25-2.26-4.03-10.32
P/OCF Ratio
--2.11-2.26-2.28-4.12-11.51
EV/Sales Ratio
--11035.441905.163117.4315.26
EV/EBITDA Ratio
--0.71-0.94-0.58-1.51-10.25
EV/EBIT Ratio
--0.66-0.89-0.55-1.45-9.66
EV/FCF Ratio
--0.93-1.21-0.76-2.15-8.44
Debt / Equity Ratio
0.260.260.200.170.140.08
Debt / EBITDA Ratio
-0.38-0.38-0.32-0.28-0.30-0.41
Debt / FCF Ratio
-0.50-0.50-0.41-0.37-0.42-0.34
Net Debt / Equity Ratio
-0.60-0.60-0.50-0.70-0.63-0.42
Net Debt / EBITDA Ratio
0.890.890.811.151.312.28
Net Debt / FCF Ratio
1.171.171.041.511.871.88
Asset Turnover
-00.000.000.000.10
Quick Ratio
7.707.708.2312.109.639.55
Current Ratio
7.937.938.5412.389.849.84
Return on Equity (ROE)
-53.42%-53.42%-54.94%-55.51%-42.76%-18.16%
Return on Assets (ROA)
-43.40%-43.40%-45.78%-44.76%-35.84%-15.82%
Return on Invested Capital (ROIC)
-118.29%-118.29%-144.39%-160.78%-84.26%-40.48%
Return on Capital Employed (ROCE)
-46.69%-46.69%-48.83%-47.72%-37.90%-16.87%
Earnings Yield
-32.09%-63.50%-61.97%-65.11%-37.84%-8.98%
FCF Yield
-25.16%-47.61%-44.47%-44.20%-24.84%-9.69%
Buyback Yield / Dilution
-7.40%-7.40%-25.31%-17.68%-0.32%-0.56%
Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q